Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
Protocol ID
APAL2020D
Disease (Sub Disease)
Acute myeloid leukemia
Diagnosis Stage
Relapsed/refractory
Sponsor
LLS PedAL Initiative, LLC
Collaborators
Princess Maxima Center for Pediatric Oncology (European Sponsor)
AbbVie
Roche-Genentech
EuPAL
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 3
Age Eligibility
29 Days to 21 Years
International registry ID's
NCT05183035
Back to Registry
Study Title A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
Protocol ID APAL2020D
Disease (Sub Disease) Acute myeloid leukemia
Diagnosis Stage Relapsed/refractory
Sponsor LLS PedAL Initiative, LLC
Collaborators Princess Maxima Center for Pediatric Oncology (European Sponsor)/ AbbVie/ Roche-Genentech/ EuPAL
Links https://clinicaltrials.gov/ct2/show/NCT05183035
Trial Status Preparing to Open
Study Type Treatment
Phase Phase 3
Age Eligibility 29 Days to 21 Years
International registry ID's NCT05183035